ArticleZhongguo fei ai za zhi = Chinese journal of lung cancer2017
[Aberrant Expression of Rb and pRb-780, pRb-795 in Lung Adenocarcinoma Patients with EGFR Mutations and Their Clinical Significance].
Article in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRb is an important tumor suppressor gene that regulates cell cycle progression. Rb dysfunction can lead to over proliferation of cells and lead to the occurrence of tumor. Loss or reduced Rb expression as well as over phosphorylation of Rb are important mechanisms of Rb dysfunction. The mutated epidermal growth factor receptor (EGFR) gene is an important driver gene in lung adenocarcinoma, and plays an important role in the development of lung cancer. The purpose of this study was to investigate the status of Rb in lung adenocarcinoma patients with EGFR mutations and define the clinicopathologic features.
methods23 cases pulmonary adenocarcinoma patients with EGFR mutations were collected. The status of Rb and pRb-780, pRb-795 were determined byimmunohistochemistry.
resultsLoss or reduced Rb expression were detected in 16 of 23 samples (69.6%). pRb-780 and pRb-795 over-expressed were identified in 17 (73.9%) and 16 (69.6%) of 23 samples respectively. All the 23 patients had showed loss/reduced Rb expression or over-expressed Rb phosphorylation. Further analysis showed that over expression of pRb-780 and pRb-795 occurred more frequently in advanced patients.
conclusionsAberrant expressionof Rb is frequently occurred in lung adenocarcinoma patients with EGFR mutations and may be an important pathogenesis in patients with lung adenocarcinoma. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.